Sangamo TherapeuticsSGMO
About: Sangamo Therapeutics Inc is a genomic medicine company committed to translating ground-breaking science into medicines that transform the lives of patients and families afflicted with serious neurological diseases. Its pipeline products include the Priority Neurology Pipeline offers Chronic Neuropathic Pain, Prion Disease, and Neurology; Partnered Programs offer Hemophilia A, Oncology, ALS/FTD, and Huntington's Disease; and Other Pipelines include Fabry Disease, Renal Transplant, Inflammatory Bowel Disease, and Multiple Sclerosis.
Employees: 183
Fund manager confidence
Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)
156% more first-time investments, than exits
New positions opened: 41 | Existing positions closed: 16
30% more capital invested
Capital invested by funds: $48.4M [Q3] → $62.8M (+$14.4M) [Q4]
23% more funds holding
Funds holding: 103 [Q3] → 127 (+24) [Q4]
2.62% more ownership
Funds ownership: 26.86% [Q3] → 29.48% (+2.62%) [Q4]
7% more repeat investments, than reductions
Existing positions increased: 32 | Existing positions reduced: 30
44% less call options, than puts
Call options by funds: $1.87M | Put options by funds: $3.36M
Research analyst outlook
2 Wall Street Analysts provided 1 year price targets over the past 3 months
2 analyst ratings
HC Wainwright & Co. Patrick Trucchio 21% 1-year accuracy 40 / 187 met price target | 1,171%upside $10 | Buy Reiterated | 7 Apr 2025 |
RBC Capital Luca Issi 17% 1-year accuracy 9 / 54 met price target | 154%upside $2 | Sector Perform Reiterated | 18 Mar 2025 |
Financial journalist opinion









